Verve Therapeutics Inc (VERV)
6.35
+0.31
(+5.13%)
USD |
NASDAQ |
Nov 05, 16:00
6.35
0.00 (0.00%)
After-Hours: 16:20
Verve Therapeutics Shareholders Equity (Quarterly): 546.09M for June 30, 2024
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 546.09M |
| March 31, 2024 | 583.07M |
| December 31, 2023 | 599.50M |
| September 30, 2023 | 460.37M |
| June 30, 2023 | 465.22M |
| March 31, 2023 | 509.48M |
| December 31, 2022 | 550.93M |
| September 30, 2022 | 547.94M |
| Date | Value |
|---|---|
| June 30, 2022 | 296.33M |
| March 31, 2022 | 331.39M |
| December 31, 2021 | 357.35M |
| September 30, 2021 | 384.94M |
| June 30, 2021 | 405.40M |
| March 31, 2021 | -76.43M |
| December 31, 2020 | -63.91M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
-76.43M
Minimum
Mar 2021
599.50M
Maximum
Dec 2023
393.18M
Average
460.37M
Median
Sep 2023
Shareholders Equity (Quarterly) Benchmarks
| Ardelyx Inc | 158.30M |
| Biomarin Pharmaceutical Inc | 5.413B |
| Sage Therapeutics Inc | 551.84M |
| ALX Oncology Holdings Inc | 159.32M |
| Immuneering Corp | 66.31M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 700.91M |
| Total Liabilities (Quarterly) | 154.82M |
| Current Ratio | 14.64 |